Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Frequency of EGFR KRAS

Frequency of EGFR KRAS ORIGINAL ARTICLE Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans J. Matthew Reinersman, MD,* Melissa L. Johnson, MD,† Gregory J. Riely, MD, PhD,† Dhananjay A. Chitale, MD,* Anthony D. Nicastri, MD,‡ Gerald A. Soff, MD,** Ann G. Schwartz, MD,§ Camelia S. Sima, MD, MS, Getinet Ayalew, MD,‡ Christopher Lau, PhD,¶ Maureen F. Zakowski, MD,¶ Valerie W. Rusch, MD,# Marc Ladanyi, MD,*¶ and Mark G. Kris, MD† 0.11). KRAS mutations were more likely among whites, 26% (125/ Introduction: The detection of mutations in the epidermal growth 476, 95% CI: 23–30%; p  0.04). factor receptor (EGFR) gene, which predict sensitivity to treatment Conclusions: This is the largest study to date examining the fre- with EGFR tyrosine kinase inhibitors, represents a major advance in quency of mutations in lung adenocarcinomas in African Americans. the treatment of lung adenocarcinoma. KRAS mutations confer Although KRAS mutations were somewhat less likely, there was no resistance to EGFR-tyrosine kinase inhibitors. The prevalence of difference between the frequencies of EGFR mutations in African these mutations in African American patients has not been thor- American patients, when compared with whites. These results sug- oughly investigated. gest that all patients with advanced lung adenocarcinomas http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Frequency of EGFR KRAS

Kris, Mark G.
Journal of Thoracic Oncology , Volume 6 (1) – Jan 1, 2011
Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/frequency-of-egfr-kras-ObbHm6doUL

References (21)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181fb4fe2
pmid
21107288
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans J. Matthew Reinersman, MD,* Melissa L. Johnson, MD,† Gregory J. Riely, MD, PhD,† Dhananjay A. Chitale, MD,* Anthony D. Nicastri, MD,‡ Gerald A. Soff, MD,** Ann G. Schwartz, MD,§ Camelia S. Sima, MD, MS, Getinet Ayalew, MD,‡ Christopher Lau, PhD,¶ Maureen F. Zakowski, MD,¶ Valerie W. Rusch, MD,# Marc Ladanyi, MD,*¶ and Mark G. Kris, MD† 0.11). KRAS mutations were more likely among whites, 26% (125/ Introduction: The detection of mutations in the epidermal growth 476, 95% CI: 23–30%; p  0.04). factor receptor (EGFR) gene, which predict sensitivity to treatment Conclusions: This is the largest study to date examining the fre- with EGFR tyrosine kinase inhibitors, represents a major advance in quency of mutations in lung adenocarcinomas in African Americans. the treatment of lung adenocarcinoma. KRAS mutations confer Although KRAS mutations were somewhat less likely, there was no resistance to EGFR-tyrosine kinase inhibitors. The prevalence of difference between the frequencies of EGFR mutations in African these mutations in African American patients has not been thor- American patients, when compared with whites. These results sug- oughly investigated. gest that all patients with advanced lung adenocarcinomas

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2011

There are no references for this article.